Madrid
Updated:
Save
Patients with de novo hormone-sensitive metastatic prostate cancer -those who at the time of diagnosis already have metastatic-stage disease- could finally have a treatment that improves their survival. Data from a study carried out by the European consortium PEACE show that triple systemic therapy is capable of improving both progression-free survival and overall survival in these patients. In addition, the treatment could become a standard of care.
Published in the journal The Lancet, the study aimed to assess the efficacy and safety of adding abiraterone, a second-generation androgen biosynthesis inhibitor drug, along with prednisone to combined androgen suppression therapy and docetaxel, a chemotherapy drug.